Logotype for Cingulate Inc

Cingulate (CING) investor relations material

Cingulate Q2 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Cingulate Inc
Q2 2025 earnings summary19 Aug, 2025

Executive summary

  • NDA for lead candidate CTx-1301, a novel extended-release ADHD treatment, submitted to FDA on July 31, 2025; FDA decision on acceptance expected in Q4 2025 and potential PDUFA date in mid-2026; PDUFA fee waiver received.

  • Positive Phase 3 pediatric and high-dose fed/fast study results for CTx-1301 support efficacy and flexible dosing.

  • No product candidates approved or revenue generated as of June 30, 2025; operations funded by $113.5M in capital raised since inception.

  • Recent management changes: CEO placed on leave due to legal proceedings, CFO appointed interim CEO, and new Executive Chairman named.

  • Entered a $25M equity purchase agreement with Lincoln Park Capital in July 2025 to support pre-commercial activities.

Financial highlights

  • Net loss for Q2 2025 was $4.8M, up 49.2% year-over-year, driven by higher R&D and G&A expenses; six-month net loss was $8.6M, up 39% year-over-year.

  • Cash and cash equivalents were $8.9M as of June 30, 2025, down $3.3M from December 31, 2024.

  • Working capital stood at $3.5M, a decrease of $4.2M from year-end 2024.

  • Operating expenses for Q2 2025: R&D $2.7M (up 43.6%), G&A $1.9M (up 47.1%).

  • Accumulated deficit reached $117.1M as of June 30, 2025.

Outlook and guidance

  • Cash expected to fund operations into late 2025; $1.5M additional capital needed to advance CTx-1301 commercialization into early 2026.

  • Additional capital required for further development of pipeline assets.

  • Anticipates FDA decision on NDA acceptance in Q4 2025 and potential product launch in mid-2026, pending approval.

  • Ongoing evaluation of equity, debt, and strategic transactions for funding.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Cingulate earnings date

Logotype for Cingulate Inc
Q3 20256 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Cingulate earnings date

Logotype for Cingulate Inc
Q3 20256 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Cingulate Inc. is a biopharmaceutical company focused on developing treatments for central nervous system disorders. The company specializes in precision drug delivery technology to enhance the efficacy and control of medications. Its primary research targets attention-deficit/hyperactivity disorder (ADHD) and other cognitive and psychiatric conditions. Cingulate leverages its proprietary Precision Timed Release (PTR) platform to develop extended-release formulations for improved patient outcomes. The company is headquartered in Kansas City, Kansas, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage